An antidepressant in use for decades, repurposed to fight prostate cancer, shows promise in helping patients whose disease has returned following surgery or radiation, a pilot study at USC shows.
The drug — an MAO inhibitor called phenelzine — represents a⦠[+4442 chars]Source
